CAR-ving a Path: Metalloprotease-Engineered CAR T Cells Tunnel through Solid Tumors.

IF 8.2 1区医学 Q1 IMMUNOLOGY

Cancer immunology research Pub Date : 2025-10-08 DOI:10.1158/2326-6066.CIR-25-1097

Alessandro Gasparetto, Roberto Chiarle

引用次数: 0

Abstract

Overcoming the physical barriers of the tumor microenvironment remains a major obstacle for chimeric antigen receptor (CAR) T-cell therapy in solid tumors. In this issue, Van Pelt and colleagues show that engineering GD2-targeting CAR T cells to express matrix metalloproteinase 7 and osteopontin-b enhances their ability to infiltrate tumors rich in extracellular matrix. These modifications improve functionality in preclinical models without increasing off-target toxicity. The findings highlight a promising strategy to design CAR T cells with extracellular matrix-remodeling capabilities. See related article by Van Pelt et al., p. XX .

查看原文本刊更多论文

CAR- T细胞通道：金属蛋白酶工程CAR- T细胞穿过实体肿瘤

克服肿瘤微环境的物理障碍仍然是嵌合抗原受体（CAR） t细胞治疗实体瘤的主要障碍。在这一期中，Van Pelt和他的同事们表明，通过工程化gd2靶向CAR - T细胞表达基质金属蛋白酶7和骨桥蛋白-b，可以增强它们浸润富含细胞外基质的肿瘤的能力。这些修饰改善了临床前模型的功能，而不增加脱靶毒性。这些发现强调了一种设计具有细胞外基质重塑能力的CAR - T细胞的有希望的策略。参见Van Pelt等人的相关文章，第XX页。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer immunology research ONCOLOGY-IMMUNOLOGY

CiteScore

15.60

自引率

1.00%

发文量

260

期刊介绍： Cancer Immunology Research publishes exceptional original articles showcasing significant breakthroughs across the spectrum of cancer immunology. From fundamental inquiries into host-tumor interactions to developmental therapeutics, early translational studies, and comprehensive analyses of late-stage clinical trials, the journal provides a comprehensive view of the discipline. In addition to original research, the journal features reviews and opinion pieces of broad significance, fostering cross-disciplinary collaboration within the cancer research community. Serving as a premier resource for immunology knowledge in cancer research, the journal drives deeper insights into the host-tumor relationship, potent cancer treatments, and enhanced clinical outcomes. Key areas of interest include endogenous antitumor immunity, tumor-promoting inflammation, cancer antigens, vaccines, antibodies, cellular therapy, cytokines, immune regulation, immune suppression, immunomodulatory effects of cancer treatment, emerging technologies, and insightful clinical investigations with immunological implications.